{"id":"https://openalex.org/W4283373531","doi":"https://doi.org/10.1097/01.hs9.0000844036.02998.15","title":"S286: LONG-TERM EFFICACY AND SAFETY RESULTS FROM AN ONGOING OPEN-LABEL PHASE 2 STUDY OF PARSACLISIB FOR THE TREATMENT OF AUTOIMMUNE HEMOLYTIC ANEMIA (AIHA)","display_name":"S286: LONG-TERM EFFICACY AND SAFETY RESULTS FROM AN ONGOING OPEN-LABEL PHASE 2 STUDY OF PARSACLISIB FOR THE TREATMENT OF AUTOIMMUNE HEMOLYTIC ANEMIA (AIHA)","publication_year":2022,"publication_date":"2022-06-01","ids":{"openalex":"https://openalex.org/W4283373531","doi":"https://doi.org/10.1097/01.hs9.0000844036.02998.15"},"language":"en","primary_location":{"id":"doi:10.1097/01.hs9.0000844036.02998.15","doi":"https://doi.org/10.1097/01.hs9.0000844036.02998.15","is_oa":true,"landing_page_url":"https://doi.org/10.1097/01.hs9.0000844036.02998.15","pdf_url":null,"source":{"id":"https://openalex.org/S4210211592","display_name":"HemaSphere","issn_l":"2572-9241","issn":["2572-9241"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-2","norway-1","oarl","poland-20","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310318547","host_organization_name":"Wolters Kluwer","host_organization_lineage":["https://openalex.org/P4310318547"],"host_organization_lineage_names":["Wolters Kluwer"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"HemaSphere","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1097/01.hs9.0000844036.02998.15","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5034535532","display_name":"Wilma Barcellini","orcid":"https://orcid.org/0000-0003-1428-9944","observed_orcids":["https://orcid.org/0000-0003-1428-9944"]},"institutions":[{"id":"https://openalex.org/I2803066834","display_name":"Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico","ror":"https://ror.org/016zn0y21","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I189158943","https://openalex.org/I2803066834","https://openalex.org/I4210153126"]}],"countries":["IT"],"is_corresponding":true,"raw_author_name":"W. Barcellini","raw_affiliation_strings":["Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Milan, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Milan, Italy","institution_ids":["https://openalex.org/I2803066834"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055504879","display_name":"Irina Murakhovskaya","orcid":"https://orcid.org/0000-0001-6136-6573","observed_orcids":["https://orcid.org/0000-0001-6136-6573"]},"institutions":[{"id":"https://openalex.org/I129975664","display_name":"Albert Einstein College of Medicine","ror":"https://ror.org/05cf8a891","country_code":"US","type":"education","lineage":["https://openalex.org/I129975664","https://openalex.org/I4210112371"]},{"id":"https://openalex.org/I1335289525","display_name":"Montefiore Medical Center","ror":"https://ror.org/044ntvm43","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1335289525","https://openalex.org/I19772626"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"I. Murakhovskaya","raw_affiliation_strings":["Albert Einstein College of Medicine/Montefiore Medical Center Bronx, New York, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Albert Einstein College of Medicine/Montefiore Medical Center Bronx, New York, United States of America","institution_ids":["https://openalex.org/I129975664","https://openalex.org/I1335289525"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055188307","display_name":"Louis Terriou","orcid":"https://orcid.org/0000-0001-5919-9956","observed_orcids":["https://orcid.org/0000-0001-5919-9956","https://orcid.org/0000-0002-2917-8748"]},"institutions":[{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I2279609970","display_name":"Universit\u00e9 de Lille","ror":"https://ror.org/02kzqn938","country_code":"FR","type":"education","lineage":["https://openalex.org/I2279609970"]},{"id":"https://openalex.org/I3018718406","display_name":"Centre Hospitalier Universitaire de Lille","ror":"https://ror.org/02ppyfa04","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I3018718406"]},{"id":"https://openalex.org/I4387152267","display_name":"Institute for Translational Research in Inflammation","ror":"https://ror.org/03qy9z186","country_code":"FR","type":"facility","lineage":["https://openalex.org/I154526488","https://openalex.org/I2279609970","https://openalex.org/I3018718406","https://openalex.org/I4387152267"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"L. Terriou","raw_affiliation_strings":["Univ. Lille, Inserm, CHU Lille, Centre de R\u00e9f\u00e9rence des Maladies Autoimmunes Syst\u00e9miques Rares du Nord et Nord-Ouest de France (CeRAINO), INFINITE \u2013 Institute for Translational Research in Inflammation, Lille, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Univ. Lille, Inserm, CHU Lille, Centre de R\u00e9f\u00e9rence des Maladies Autoimmunes Syst\u00e9miques Rares du Nord et Nord-Ouest de France (CeRAINO), INFINITE \u2013 Institute for Translational Research in Inflammation, Lille, France","institution_ids":["https://openalex.org/I154526488","https://openalex.org/I2279609970","https://openalex.org/I3018718406","https://openalex.org/I4387152267"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111348492","display_name":"Francesco Pane","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I71267560","display_name":"University of Naples Federico II","ror":"https://ror.org/05290cv24","country_code":"IT","type":"education","lineage":["https://openalex.org/I71267560"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"F. Pane","raw_affiliation_strings":["University of Naples \u201cFederico II\u201d, Naples"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Naples \u201cFederico II\u201d, Naples","institution_ids":["https://openalex.org/I71267560"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066726265","display_name":"A. Patriarca","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I123338534","display_name":"Universit\u00e0 degli Studi del Piemonte Orientale \u201cAmedeo Avogadro\u201d","ror":"https://ror.org/04387x656","country_code":"IT","type":"education","lineage":["https://openalex.org/I123338534"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"A. Patriarca","raw_affiliation_strings":["University of Eastern Piedmont and AOU \u201cMaggiore della Carit\u00e0\u201d, Novara, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Eastern Piedmont and AOU \u201cMaggiore della Carit\u00e0\u201d, Novara, Italy","institution_ids":["https://openalex.org/I123338534"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040173544","display_name":"Kathleen A. Butler","orcid":"https://orcid.org/0000-0002-6907-0846","observed_orcids":["https://orcid.org/0000-0002-6907-0846"]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"K. Butler","raw_affiliation_strings":["Incyte Corporation, Wilmington, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation, Wilmington, United States of America","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034706334","display_name":"S. Moran","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S. Moran","raw_affiliation_strings":["Incyte Corporation, Wilmington, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation, Wilmington, United States of America","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076592971","display_name":"Shaoceng Wei","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S. Wei","raw_affiliation_strings":["Incyte Corporation, Wilmington, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation, Wilmington, United States of America","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5113865605","display_name":"Ulrich Jaeger","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I76134821","display_name":"Medical University of Vienna","ror":"https://ror.org/05n3x4p02","country_code":"AT","type":"education","lineage":["https://openalex.org/I76134821"]}],"countries":["AT"],"is_corresponding":false,"raw_author_name":"U. J\u00e4ger","raw_affiliation_strings":["Medical University of Vienna, Vienna, Austria"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical University of Vienna, Vienna, Austria","institution_ids":["https://openalex.org/I76134821"]}]}],"institutions":[],"countries_distinct_count":4,"institutions_distinct_count":11,"corresponding_author_ids":["https://openalex.org/A5034535532"],"corresponding_institution_ids":["https://openalex.org/I2803066834"],"apc_list":{"value":2480,"currency":"USD","value_usd":2480},"apc_paid":{"value":2480,"currency":"USD","value_usd":2480},"fwci":1.2723,"has_fulltext":false,"cited_by_count":9,"citation_normalized_percentile":{"value":0.80530464,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":97},"biblio":{"volume":"6","issue":null,"first_page":"187","last_page":"188"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11660","display_name":"Blood groups and transfusion","score":0.9818999767303467,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11660","display_name":"Blood groups and transfusion","score":0.9818999767303467,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10554","display_name":"Hemoglobinopathies and Related Disorders","score":0.005799999926239252,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10308","display_name":"Systemic Lupus Erythematosus Research","score":0.0034000000450760126,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/parsaclisib","display_name":"parsaclisib","score":0.9750000238418579},{"id":"https://openalex.org/keywords/autoimmune-hemolytic-anemia","display_name":"autoimmune hemolytic anemia","score":0.9739999771118164},{"id":"https://openalex.org/keywords/warm-autoimmune-hemolytic-anemia","display_name":"warm autoimmune hemolytic anemia","score":0.9079999923706055},{"id":"https://openalex.org/keywords/cold-agglutinin-disease","display_name":"cold agglutinin disease","score":0.9980000257492065},{"id":"https://openalex.org/keywords/treatment-emergent-adverse-events","display_name":"treatment-emergent adverse events","score":0.781000018119812},{"id":"https://openalex.org/keywords/complete-response","display_name":"complete response","score":0.5149999856948853},{"id":"https://openalex.org/keywords/partial-response","display_name":"partial response","score":0.6480000019073486},{"id":"https://openalex.org/keywords/long-term-safety","display_name":"long-term safety","score":0.42800000309944153},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.33899998664855957}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8201769590377808},{"id":"https://openalex.org/C2777385706","wikidata":"https://www.wikidata.org/wiki/Q28814","display_name":"Autoimmune hemolytic anemia","level":3,"score":0.704185962677002},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.6524180769920349},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.6457335948944092},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6300745010375977},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6164504885673523},{"id":"https://openalex.org/C2778248108","wikidata":"https://www.wikidata.org/wiki/Q5445","display_name":"Anemia","level":2,"score":0.5692234635353088},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.516026496887207},{"id":"https://openalex.org/C2779384505","wikidata":"https://www.wikidata.org/wiki/Q17007513","display_name":"Concomitant","level":2,"score":0.5023107528686523},{"id":"https://openalex.org/C2778720950","wikidata":"https://www.wikidata.org/wiki/Q424972","display_name":"Prednisone","level":2,"score":0.49787473678588867},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.49730709195137024},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.4566234350204468},{"id":"https://openalex.org/C2777884830","wikidata":"https://www.wikidata.org/wiki/Q3961632","display_name":"Cold agglutinin disease","level":4,"score":0.44950592517852783},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.4236915707588196},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.335823118686676},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.243137389421463},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.14775657653808594},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.11913591623306274}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1097/01.hs9.0000844036.02998.15","doi":"https://doi.org/10.1097/01.hs9.0000844036.02998.15","is_oa":true,"landing_page_url":"https://doi.org/10.1097/01.hs9.0000844036.02998.15","pdf_url":null,"source":{"id":"https://openalex.org/S4210211592","display_name":"HemaSphere","issn_l":"2572-9241","issn":["2572-9241"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-2","norway-1","oarl","poland-20","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310318547","host_organization_name":"Wolters Kluwer","host_organization_lineage":["https://openalex.org/P4310318547"],"host_organization_lineage_names":["Wolters Kluwer"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"HemaSphere","raw_type":"journal-article"},{"id":"pmh:oai:doaj.org/article:ed3609d080ef4e11907c126ef371a713","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/ed3609d080ef4e11907c126ef371a713","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"HemaSphere, Vol 6, Pp 187-188 (2022)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1097/01.hs9.0000844036.02998.15","doi":"https://doi.org/10.1097/01.hs9.0000844036.02998.15","is_oa":true,"landing_page_url":"https://doi.org/10.1097/01.hs9.0000844036.02998.15","pdf_url":null,"source":{"id":"https://openalex.org/S4210211592","display_name":"HemaSphere","issn_l":"2572-9241","issn":["2572-9241"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-2","norway-1","oarl","poland-20","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310318547","host_organization_name":"Wolters Kluwer","host_organization_lineage":["https://openalex.org/P4310318547"],"host_organization_lineage_names":["Wolters Kluwer"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"HemaSphere","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4403648166","https://openalex.org/W4283371536","https://openalex.org/W4390786280","https://openalex.org/W2586538714","https://openalex.org/W7035922751","https://openalex.org/W7159967419","https://openalex.org/W3011127288","https://openalex.org/W4410630683","https://openalex.org/W2018291353","https://openalex.org/W3011339488"],"abstract_inverted_index":{"Background:":[0],"AIHA":[1,45,54],"is":[2,583],"a":[3,88,575],"rare":[4],"condition":[5],"caused":[6],"by":[7,440],"autoantibody-mediated":[8],"hemolysis":[9],"of":[10,35,69,91,151,168,191,207,233,322,436,447,556],"red":[11],"blood":[12],"cells.":[13],"Few":[14],"therapies":[15],"beyond":[16],"steroids":[17],"and":[18,67,199,214,239,246,262,276,300,326,331,358,368,443,463,480,494,541,558,574],"rituximab":[19],"are":[20],"available.":[21],"Aims:":[22],"To":[23],"report":[24],"updated":[25],"results":[26],"from":[27,188,196,308,337],"an":[28,160,568],"ongoing":[29],"multicenter,":[30],"phase":[31,578],"2,":[32,225],"open-label":[33],"study":[34],"the":[36,283,343,355,364,373,428,451,527,562],"phosphoinositide":[37],"3-kinase-\u03b4":[38],"inhibitor":[39],"parsaclisib":[40,83,156,216,287,518],"in":[41,112,135,282,350,354,379,396,419,468,483,526,543,581],"patients":[42],"(pts)":[43],"with":[44,52,81,170,221,313,347,361,392,414,478],"(NCT03538041).":[46],"Methods:":[47],"Pts":[48],"\u226518":[49],"years":[50],"old":[51],"warm":[53],"(wAIHA),":[55],"cold":[56],"agglutinin":[57],"disease":[58],"(CAD),":[59],"or":[60,99,177,184],"mixed-type":[61],"AIHA;":[62],"hemoglobin":[63],"(Hgb)":[64],"7\u201310":[65],"g/dL;":[66],"failure":[68,525],"\u22651":[70,458],"standard":[71],"therapy":[72],"were":[73,79,110,133,146,165,260,265,446,465,507,559],"eligible.":[74],"After":[75,148],"informed":[76],"consent,":[77],"pts":[78,153,169,212,228,242,258,278,296,312,317,341,360,381,385,402,409,425,445,455,470,473,513],"treated":[80],"oral":[82,570],"for":[84,138,572],"12":[85,149,231,320,327,554],"wk":[86,117,150,232,321,555],"at":[87,193,270,305,334],"starting":[89],"dose":[90,222],"1.0":[92,130],"mg":[93,101,108,131],"once":[94],"daily":[95],"(QD;":[96],"cohort":[97,113,136,224,357],"1)":[98],"2.5":[100,107],"QD":[102,109,132],"(cohort":[103,217],"2).":[104],"Increases":[105],"to":[106,129,517,533],"allowed":[111],"1":[114],"after":[115],"6":[116,237],"if":[118],"no":[119],"clinical":[120],"response":[121,172,179],"was":[122,126,253,272,289,352,530,537],"achieved":[123,298,329],"and/or":[124],"transfusion":[125],"required;":[127],"reductions":[128],"permitted":[134],"2":[137,401,444,550],"tolerability":[139],"issues.":[140],"Concomitant":[141],"corticosteroids":[142],"(\u226420":[143],"mg/d":[144],"prednisone)":[145],"allowed.":[147],"treatment,":[152],"responding":[154],"on":[155],"could":[157],"continue":[158],"into":[159],"extension":[161,344,369,452,528,563],"period.":[162,564],"Primary":[163],"endpoints":[164],"efficacy":[166,437],"(proportion":[167],"complete":[171],"[CR;":[173],"Hgb":[174,181,269,351,544],"\u226512":[175],"g/dL]":[176],"partial":[178],"[PR;":[180],"10\u201312":[182],"g/dL":[183,186],"\u22652":[185],"increase":[187],"baseline,":[189],"inclusive":[190],"CRs]":[192],"any":[194,306,335],"visit":[195,307,336],"Wk":[197,309,338,549],"6\u201312)":[198],"safety":[200],"(treatment-emergent":[201],"adverse":[202],"events":[203],"[TEAEs]).":[204],"Results:":[205],"As":[206],"Aug":[208],"5,":[209],"2021,":[210],"25":[211],"enrolled":[213],"received":[215],"1,":[218],"n=10":[219],"[8":[220],"increase];":[223],"n=15);":[226],"20":[227],"(80%)":[229],"completed":[230,319],"treatment.":[234],"Sixteen":[235],"(64%),":[236],"(24%),":[238],"3":[240,491,495,579],"(12%)":[241,512],"had":[243,280,303,387,404,411,475,514],"wAIHA,":[244],"CAD,":[245],"mixed":[247],"AIHA,":[248,573],"respectively.":[249],"Mean":[250,267,286],"(SD)":[251,268],"age":[252],"61.6":[254],"(17.0)":[255],"years;":[256],"14":[257,316],"(56%)":[259],"female":[261],"23":[263],"(92%)":[264],"White.":[266],"baseline":[271],"8.9":[273],"(0.8)":[274],"g/dL,":[275],"9":[277,469],"(36%)":[279],"transfusions":[281],"past":[284],"year.":[285],"exposure":[288],"334":[290],"(range,":[291],"7\u2013819)":[292],"days.":[293],"Overall,":[294],"8":[295,324],"(32%)":[297],"CR":[299,330],"16":[301],"(64%)":[302],"PR":[304],"6\u201312.":[310,339],"Among":[311],"wAIHA":[314,362,582],"(n=16),":[315],"(88%)":[318,456],"treatment;":[323],"(50%)":[325],"(75%)":[328],"PR,":[332],"respectively,":[333],"Seventeen":[340],"entered":[342],"period":[345,431],"(12":[346],"wAIHA).":[348],"Increase":[349],"sustained":[353,560],"total":[356],"among":[359],"during":[363,427],"initial":[365],"12-wk":[366,374,429],"treatment":[367,375,430,509,557,571],"periods":[370],"(Figure).":[371],"During":[372,450],"period,":[376,453],"TEAEs":[377,515],"occurred":[378],"21":[380],"(84%)":[382],"overall.":[383],"Six":[384,472],"(24%)":[386],"grade":[388],"(Gr)":[389],"\u22653":[390,461],"TEAEs,":[391],"only":[393,415],"neutropenia":[394],"occurring":[395],">1":[397,420,484],"pt":[398,421,485],"(n=2":[399,422,486],"[8%]);":[400],"(8%)":[403],"serious":[405],"AEs":[406,462],"(SAEs).":[407],"Seven":[408],"(28%)":[410],"treatment-related":[412,476],"AEs,":[413,477],"pruritic":[416],"rash":[417,481],"reported":[418,467,482],"[8%]).":[423],"Three":[424],"discontinued":[426],"(AE":[432],"[n=1;":[433],"thrombocytopenia],":[434],"lack":[435],"[n=1],":[438],"withdrawal":[439],"subject":[441],"[n=1]),":[442],"unknown":[448],"status.":[449],"15/17":[454],"experienced":[457],"TEAE.":[459],"Gr":[460,490],"SAEs":[464,496],"each":[466],"(53%).":[471],"(35%)":[474],"diarrhea":[479],"[12%]":[487],"each).":[488],"One":[489,520],"TEAE":[492,522],"(psoriasis)":[493],"(diarrhea":[497],"[Gr":[498,502,505],"2],":[499,503],"cytomegalovirus":[500],"reactivation":[501],"psoriasis":[504],"3])":[506],"deemed":[508,531],"related.":[510],"Two":[511],"leading":[516],"discontinuation.":[519],"fatal":[521],"(acute":[523],"respiratory":[524],"period)":[529],"unrelated":[532],"parsaclisib.":[534],"Image:Summary/Conclusion:":[535],"Parsaclisib":[536,565],"generally":[538],"well":[539],"tolerated":[540],"resulted":[542],"improvements":[545],"as":[546,548],"early":[547],"that":[551],"increased":[552],"over":[553],"through":[561],"may":[566],"be":[567],"effective":[569],"randomized,":[576],"controlled":[577],"trial":[580],"now":[584],"recruiting":[585],"(NCT05073458).":[586]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":4}],"updated_date":"2026-10-30T12:39:25.321706","created_date":"2022-06-25T00:00:00"}